Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by 89bio, Inc. < Previous 1 2 Next > 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024 October 15, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 11, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference September 30, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 19, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer September 16, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio to Participate in Upcoming Investor Conferences August 29, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Appoints Francis Sarena as Chief Operating Officer August 07, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Reports Second Quarter 2024 Financial Results and Corporate Updates August 05, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Appoints Charles McWherter, Ph.D., to its Board of Directors August 05, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 12, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 14, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress May 22, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis May 14, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio to Participate in the BofA Securities 2024 Health Care Conference May 08, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH May 02, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors April 17, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 05, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis March 27, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis March 12, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 08, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio to Participate in the Leerink Partners Global Biopharma Conference March 05, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates February 29, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 06, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 05, 2024 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 19, 2023 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares December 12, 2023 From 89bio, Inc. Via GlobeNewswire Tickers ETNB 89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants December 07, 2023 From 89bio, Inc. Via GlobeNewswire Tickers ETNB < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
